What do long-term outcome studies show about treated versus untreated adult ADHD?
Quick answer
Long-term studies involving adults with ADHD link medication use with higher exam scores (jamanetwork.com), less long-term unemployment (jamanetwork.com) and lower death rates (jamanetwork.com), but injury findings are mixed (pmc.ncbi.nlm.nih.gov). These are observational associations, not proof that treatment caused the differences or a prediction for any individual.
Treated usually means medication, not every kind of support
Not taking medication does not necessarily mean receiving no care. Counselling and practical support may still be available in a non-medication group, and these are not consistently recorded. “Untreated” is a study label, not a judgement about someone’s choices. (pmc.ncbi.nlm.nih.gov)
Registry studies link routine records such as prescriptions, hospital visits or employment registrations. Cohorts follow groups over time. Some compare different people with ADHD; others compare the same person’s medicated and unmedicated periods. (jamanetwork.com)
A target-trial emulation organises existing records to resemble a treatment trial, without actually assigning treatment at random. Years of national records can still support only a two-year outcome comparison. (jamanetwork.com)
These medication studies include stimulant medications and non-stimulant options, often pooled together. Their findings do not establish identical effects across classes, and non-use during a study does not necessarily mean lifelong non-use. (jamanetwork.com)
Education, work, injuries and mortality show different patterns
The measured differences range from modest education and employment associations to no clear change in first accidental injuries. (jamanetwork.com)
| Outcome and source | Population, design and comparison | Finding associated with medication |
|---|---|---|
| Education: Lu et al., JAMA Psychiatry, 2017 | Swedish cohort, 2006 to 2013. Within-person analysis of 930 people with ADHD, mean age 22, comparing higher-education entrance tests during medicated and unmedicated periods. | Scores averaged 4.8 points higher on a 1 to 200 scale. This measured test performance, not degree completion. (jamanetwork.com) |
| Work: Li et al., JAMA Network Open, 2022 | Registry cohort of 12,875 Swedish working-age adults, followed from 2008 to 2013. Medication in the previous two years versus none; outcome: at least 90 unemployed days in the following year. | About 10% lower relative risk, risk ratio 0.90. In the main analysis, women’s risk was 18% lower; men’s estimate was uncertain. Within-person comparisons also found lower unemployment, risk ratio 0.89. (jamanetwork.com) |
| Injuries: Zhang et al., The BMJ, 2025 | Swedish target-trial emulation: 148,581 people aged 6 to 64. Starting and continuing medication versus not starting, with two-year follow-up. | No clear reduction in first accidental injury during follow-up, rate ratio 0.98, with a 95% confidence interval of 0.96 to 1.01. When repeated injuries were counted, rates were about 4% lower. These results combine children and adults. (pmc.ncbi.nlm.nih.gov) |
| Mortality: Li et al., JAMA, 2024 | Swedish target-trial emulation: 148,578 people aged 6 to 64, comparing medication initiation within three months of diagnosis with non-initiation, with outcomes assessed over two years. | About 21% lower death rate, hazard ratio 0.79; estimated risks were 39 versus 48 per 10,000. The adult subgroup aged 25 to 64 had about an 18% lower death rate, hazard ratio 0.82. These are intention-to-treat results, not per-protocol estimates of sustained medication use. (jamanetwork.com) |
The overall mortality difference was about nine fewer deaths per 10,000 people over two years, not a 21-percentage-point change. It does not measure years of life gained. (jamanetwork.com)
For transport outcomes, see ADHD and driving risk.
Long-term treatment also needs safety monitoring
A favourable outcome in one study does not establish that medication is risk-free.
Zhang et al.’s nested case-control study, published in JAMA Psychiatry in 2024, drew on 278,027 Swedish people aged 6 to 64. It compared people with newly recorded cardiovascular disease with matched controls without it. More than five years of medication use versus non-use was associated with about 23% higher odds of cardiovascular disease, adjusted odds ratio 1.23, particularly high blood pressure. This does not mean 23% of people developed heart disease, or prove causation. (jamanetwork.com)
Unlike the mortality analysis, this study examined accumulated exposure and diagnosed disease. Different outcomes and follow-up periods mean the findings cannot simply be combined into a personal net-benefit calculation. (jamanetwork.com)
CADDRA recommends reviewing benefits and adverse effects, including blood pressure, pulse, sleep and appetite. Stimulant medications and non-stimulant options both require individual review; adverse effects vary by class. (caddra.ca)
What the evidence does not show
These studies strengthen evidence about associations without proving what would happen to the same adult under every treatment choice. (jamanetwork.com)
- Treatment selection: severity, other health conditions and access to support can influence both medication use and outcomes. Statistical adjustment cannot account for every difference. (jamanetwork.com)
- Changing circumstances: within-person comparisons control stable personal characteristics, but not necessarily changes in stress, health or other treatment. (jamanetwork.com)
- Incomplete measurement: dispensing does not prove medication was taken, and records can miss injuries that never reach medical care. (jamanetwork.com)
- Lifetime outcomes: two-year comparisons cannot establish decades of protection, effects after stopping, or years of life gained. Exam scores also do not establish graduation. (jamanetwork.com)
- Independent replication: the injury and mortality studies draw on overlapping Swedish register populations. Their sample sizes should not be added together as separate groups. (pmc.ncbi.nlm.nih.gov)
These comparisons also do not establish that treatment makes outcomes identical to those of adults without ADHD. (jamanetwork.com)
How this applies in Canada
For a Canadian adult, the practical use is shared planning and follow-up, not treating a Swedish average as a personal forecast. The estimates above are not Canadian adult outcome rates.
CADDRA’s Canadian ADHD Practice Guidelines, edition 4.1, published by the Canadian ADHD Resource Alliance in 2020, recommend individualised care combining appropriate supports and ongoing monitoring. These are clinical recommendations, not proof that guideline-based care prevents injury, unemployment or death. (caddra.ca)
Choose an outcome that matters in your week, then agree how and when to reassess it. Research averages can inform that conversation, while your functioning and unwanted effects remain central to ongoing decisions. (caddra.ca)
- Which daily-life outcome should be tracked, and how will progress be reviewed?
- How will potential benefits and unwanted effects be considered together?
- What support and follow-up are available if medication is unsuitable or not wanted?
This page is educational, not a diagnosis or personal treatment advice. These studies do not report Finding Focus outcomes.
Common questions
Related questions, answered
No. These studies do not establish a lifelong treatment schedule or tell an individual adult when to stop. Continuing, changing or ending treatment needs a review of functioning, benefits, adverse effects and preferences with the prescribing clinician. Do not use population averages to plan medication breaks. (caddra.ca)
Only cautiously. The injury and mortality cohorts mixed children and adults, while the employment cohort studied working-age adults. Their overall percentages are not teen-specific predictions. Ask the young person’s clinician to interpret evidence for their age and circumstances, rather than assuming an adult employment result applies directly. (pmc.ncbi.nlm.nih.gov)
No. Their main comparisons concern medication exposure versus non-exposure, not controlled comparisons with psychotherapy or coaching. They cannot determine which combination of supports would work for you. (pmc.ncbi.nlm.nih.gov) Those questions are covered separately in the CBT evidence and the coaching evidence.
Helpful next steps
References
- 1.Lu et al. Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder. JAMA Psychiatry, American Medical Association, 2017. View source ↗
- 2.Li et al. Association Between Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder and Long-term Unemployment Among Working-Age Individuals in Sweden. JAMA Network Open, American Medical Association, 2022. View source ↗
- 3.Zhang et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. The BMJ, BMJ Publishing Group, 2025. View source ↗
- 4.Li et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA, American Medical Association, 2024. View source ↗
- 5.Zhang et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry, American Medical Association, 2024; published online November 22, 2023. View source ↗
- 6.Canadian ADHD Resource Alliance. Canadian ADHD Practice Guidelines, edition 4.1. CADDRA, 2020. View source ↗
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional about your individual situation. If you are in crisis or thinking about self-harm, call or text 9-8-8, Canada’s Suicide Crisis Helpline, at any time.
Finding Focus uses AI tools to help research and draft some articles. Every article is edited and fact-checked by the Finding Focus team before publication. See our editorial and medical review policy.
